{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T23:38:59Z","timestamp":1775691539366,"version":"3.50.1"},"reference-count":16,"publisher":"Cambridge University Press (CUP)","issue":"9","license":[{"start":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T00:00:00Z","timestamp":1496016000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Cardiol Young"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Young children with CHD and large systemic-to-pulmonary shunts eventually develop pulmonary hypertension. At present, phosphodiesterase type-5 inhibitors such as sildenafil have been used to control pulmonary pressure before and after cardiac surgery. Recently, tadalafil has been utilised in older children with similar efficacy, but it has been used to a lesser extent in young infants. From April, 2015 to June, 2016, 42 patients aged 3\u201324 months with a large septal defect and pulmonary arterial hypertension were randomly divided into two equal groups: one group received oral sildenafil (1\u20133 mg\/kg\/day every 8 hours), whereas the other group received oral tadalafil (1 mg\/kg once a day) from 7\u201310 days before surgery to 3\u20134 weeks after surgery. During the first 48 hours after surgery, pulmonary artery-to-aortic pressure ratio and recorded systolic pulmonary artery pressures were not significantly different between the two groups (p&gt;0.05); moreover, there were no differences in paediatric ICU length of stay, mechanical ventilation time, clinical findings of low cardiac output state, and echocardiographic data between the two groups (p&gt;0.05). Most of the patients had no side effects, and only five patients had a minor with no significant difference in both groups (p=0.371). Tadalafil can be considered as an effective oral therapy for preoperative and postoperative pulmonary hypertension in young infants. It can be administered at a once-daily dose with an appropriate efficacy and safety profile as sildenafil, and therefore it can be considered as an alternative to sildenafil in young children.<\/jats:p>","DOI":"10.1017\/s1047951117000981","type":"journal-article","created":{"date-parts":[[2017,5,29]],"date-time":"2017-05-29T02:34:54Z","timestamp":1496025294000},"page":"1686-1693","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":19,"title":["Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts"],"prefix":"10.1017","volume":"27","author":[{"given":"Mohammad Reza","family":"Sabri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Bigdelian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohsen","family":"Hosseinzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehdi","family":"Ghaderian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad","family":"Shoja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2017,5,29]]},"reference":[{"key":"S1047951117000981_ref1","doi-asserted-by":"publisher","DOI":"10.1177\/021849230701500207"},{"key":"S1047951117000981_ref9","unstructured":"US Department of Health and Human Services. UFa, communication: DAFds, children FrauoRsi and hypertension. wp. FDA recommends against use of Revatio (sildenafil) in children with pulmonary hypertension, 2012."},{"key":"S1047951117000981_ref15","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000000979"},{"key":"S1047951117000981_ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-015-1238-x"},{"key":"S1047951117000981_ref7","first-page":"7","article-title":"Oral tadalafil in children with pulmonary arterial hypertension","volume":"66","author":"Shiva","year":"2016","journal-title":"Drug Res (Stuttg)"},{"key":"S1047951117000981_ref5","first-page":"211","volume-title":"Cardiac Surgery","author":"Kirklin","year":"2013"},{"key":"S1047951117000981_ref4","unstructured":"Ivy DD . Pediatric pulmonary hypertension. In: Allen HD, Shaddy RE, Penny DJ, Feltes TF and Cetta F (eds). Moss and Adams\u2019 Heart Disease in Infants, Children, and Adolescents Including the Fetus and Young Adult. Wolters Kluwer, Philadelphia, 2016: 1519\u20131558."},{"key":"S1047951117000981_ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-013-0840-z"},{"key":"S1047951117000981_ref12","first-page":"37","volume-title":"Comprehensive Surgical Management of Congenital Heart Disease","author":"Klugman","year":"2014"},{"key":"S1047951117000981_ref3","first-page":"238","article-title":"Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery","volume":"38","author":"Palma","year":"2011","journal-title":"Tex Heart Inst J"},{"key":"S1047951117000981_ref14","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000051365.81920.28"},{"key":"S1047951117000981_ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-010-2065-4"},{"key":"S1047951117000981_ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00246-012-0180-4"},{"key":"S1047951117000981_ref11","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2002.125265"},{"key":"S1047951117000981_ref16","first-page":"2","article-title":"Echocardiography in pediatric pulmonary hypertension","author":"Jone","year":"2014","journal-title":"Front Pediatr"},{"key":"S1047951117000981_ref8","unstructured":"European Medicines Agency (http:\/\/www.ema.europa.eu)."}],"container-title":["Cardiology in the Young"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1047951117000981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T21:22:08Z","timestamp":1555449728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1047951117000981\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,29]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S1047951117000981"],"URL":"https:\/\/doi.org\/10.1017\/s1047951117000981","relation":{},"ISSN":["1047-9511","1467-1107"],"issn-type":[{"value":"1047-9511","type":"print"},{"value":"1467-1107","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,29]]},"assertion":[{"value":"\u00a9 Cambridge University Press 2017\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}